---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-030299"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2024-10-01T23:59:59+00:00"
generated_at: "2026-05-30T22:58:57.654883+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CervoMed to present neflamapimod biomarker and baseline data at CTAD; topline RewinD-LB due Dec 2024

## Summary
- Two late-breaking oral presentations at CTAD in Madrid (Oct 29 – Nov 1) on neflamapimod for DLB.
- Plasma biomarker data from AscenD-LB Phase 2a study will be presented November 1.
- Baseline data from RewinD-LB Phase 2b study to be featured; CEO says increases confidence in positive outcome.
- Topline data from RewinD-LB Phase 2b study expected in December 2024.

## SEC filing metadata
- accession: 0001437749-24-030299
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2024-10-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774924030299/0001437749-24-030299-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774924030299/crvo20240930_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-030299
- JSON: https://secwatch.observer/filing/0001437749-24-030299.json
- Plain text: https://secwatch.observer/filing/0001437749-24-030299.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.